Targeted therapy was associated with better survival with both ctDNA and tissue-only matched patients.
Most patients had at least 1 biomarker test, but only 46% had all 5 biomarker tests.
Responses were observed across EGFR TKI resistance mechanisms.
The median PFS was 8.5 months in the pasireotide arm, 12.5 months in the everolimus arm, and 16.5 months in the combination arm.
The size of cancer-associated macrophage-like cells was linked to progression-free survival as well.
Overall and progression-free survival were similar between the treatment arms.